Tatyana Korolenko
Institute of Biochemistry SB RAMS, Russia
Title: Serum Cystatin C in patients with coronary stents and risk of restenosis
Biography
Biography: Tatyana Korolenko
Abstract
Objectives: To investigate whether patients with atherosclerosis after coronary stenting display altered serum cystatin C as a possible biomarker of acute ischemia.
Background: The incidence of coronary restenosis after stent placement is high, especially in the 1-year follow-up. Inflammation plays an important role in the pathogenesis of in-stent restenosis, causing neointimal proliferation through the stent meshes. Subsequent in-stent restenosis may affect the long-term safety and efficacy of angioplasty and stenting. Cystatin C was recently suggested as a candidate biomarker in cardiovascular pathology.
Methods: 34 male patients (61.8 ± 7.3 years) treated by anticoagulant therapy were enrolled in a study from the Outpatient Clinic N 1 of Novosibirsk (6 mos - 1 year after coronary stenting). The control group consisted of 25 healthy persons (50-65 years old). Serum CRP-hs, D-dimer (Architect C-8000, USA) and Cystatinc C by ELISA kit for humans (BioVendor, Czechia) were measured in all groups.
Results: In healthy persons, aged 50-65, an elevation of serum cystatin C (1.11± 0.23 mg/L, p< 0.01) was shown vs. healthy persons, aged 20-40 years. In patients with coronary stents, there was a significant increase in serum CRP-hs (p < 0.001), D-dimer (p < 0.001) and cystatin C (2.05 ± 0.21 mg/L, p < 0.001) vs the control (aged 50-65). Positive correlation was shown between cystatin C and d-Dimer in stenting patients (r = 0.45; p < 0.05).
Conclusions: Serum cystatin C is elevated in patients with coronary stenting, as well as CRP-hs, indicating on inflammation, increased risk of in-stent restenosis and ischemia.